Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics has formally requested the withdrawal of its Form S-3 registration statement (File No. 333-281864) filed on August 30, 2024. The company has decided not to proceed with the planned public offering at this time.
Key points from the withdrawal request:
- The registration statement was never declared effective by the SEC
- No securities were issued or sold under this registration
- The company acknowledges no refund will be made for filing fees
- Allarity requests that paid fees be credited to offset future registration statement costs under Rule 457(p)
The withdrawal request, submitted by CEO Thomas H. Jensen on June 24, 2025, is made pursuant to Rule 477 under the Securities Act of 1933. This action indicates a significant shift in the company's capital raising strategy and could impact its near-term financing plans.